Atherosclerotic disease (ischemic stroke, myocardial infarction or established peripheral arterial disease), prophylactically in patients at the risk of thrombo-embolic disorders such as myocardial infarction & stroke.
Platelet Aggregation Inhibitor; Anticoagulant
Clopidogrel is a prodrug. It inhibits platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets. Dose-dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses. Repeated doses of 75 mg per day inhibit ADP-induced platelet aggregation on the first day, and inhibition reaches steady state between Day 3 and Day 7.
NSAIDs, warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding
CYP2C19 inhibitors (omeprazole or esomeprazole): Avoid concomitant use of omeprazole or esomeprazole
Repaglinide (CYP2C8 substrates): Avoid concomitant use of Clopidogrel with Repaglinide as it increases plasma concentrations of Repaglinide
Hypersensitivity, Active pathological bleeding such as peptic ulcer or intracranial hemorrhage.
Hemorrhage, abdominal discomfort, nausea, vomiting, diarrhoea, headache, dizziness, vertigo, paraesthesia, rash, pruritus, hepatic & biliary disorder, neutropenia may occur.
Clopidogrel should be used in pregnant women & nursing mothers only if clearly needed.
Overdose following clopidogrel administration may lead to bleeding complications. Based on biological plausibility, platelet transfusion may restore clotting ability.
Keep below 30°C temperature in a dry place. Protected from light. Do not freeze. Keep out of the reach of children.
.png&w=384&q=75)